Although hyperlipidemia is traditionally considered a risk factor for type-2 diabetes (T2D), 22 evidence has emerged from statin trials and candidate gene investigations suggesting that lower 23 LDL-C increases T2D risk. We thus sought to comprehensively examine the phenotypic and 24 genotypic relationships of LDL-C with T2D. Using data from the UK Biobank, we found that 25 LDL-C was negatively associated with T2D (OR=0.43[0.41, 0.45] per mmol/L unit of LDL-C), 26 despite positive associations of LDL-C with HbA1c and BMI. We then performed the first 27 genome-wide exploration of variants simultaneously associated with lower LDL-C and increased 28 T2D risk, using data on LDL-C from the UK Biobank (n=431,167) and the GLGC consortium 29 (n=188,577), and T2D from the DIAGRAM consortium (n=898,130). We identified 31 loci 30 associated with lower LDL-C and increased T2D, capturing several potential mechanisms. Seven 31 of these loci have previously been identified for this phenotype, and 9 have previously been 32 implicated in non-alcoholic fatty liver disease. Finally, two-sample Mendelian randomization 33 analyses suggest that low LDL-C causes T2D, although causal interpretations are challenging 34 due to pleiotropy. Our findings extend our current understanding of the higher T2D risk among 35 individuals with low LDL-C, and of the underlying mechanisms, including those underlying the 36 diabetogenic effect of LDL-C-lowering medications.
Introduction

Statistical analyses
To evaluate and plot the prevalence of T2D, and of BMI and HbA1c, by decile of LDL-C 152 and TG in the UK Biobank, we excluded all participants who self-reported (at baseline) use of 153 cholesterol-lowering medications during the touchscreen survey, or statin medication during the 154 verbal interview. To examine levels of HbA1c by decile of LDL-C, we excluded participants 155 who self-reported T2D at the baseline visit. We further excluded individuals with outlier values 156 of HbA1c greater than four standard deviations from the mean. Deciles were calculated using the 157 'quantcut' function in the 'gtools v3.5.0' library in R. Once deciles were established, T2D 158 prevalence by LDL-C/TG deciles was calculated and plotted with confidence intervals 159 determined by the Clopper-Pearson interval (29) . Mean HbA1c and BMI and their distributions 160 are shown in boxplots for each decile of LDL-C. We further examined T2D prevalence by LDL-161 C decile separately in males and females, and in different age groups (40-49 years, 50-59 years, 162 and 60-69 years). 163 To statistically evaluate these phenotypic associations, we performed logistic regression 164 with T2D as the outcome, and linear regression with HbA1c and BMI as outcomes. For each 165 analysis, we used the same exclusion criteria as those mentioned above, and adjusted for 'last 166 eating' time (excluding individuals reporting extreme values, >16 hours), age, sex, and center.
167
To normalize residuals, we transformed LDL-C, TG cholesterol, HbA1c, and BMI by inverse 168 normalization for all linear regression analyses. In analyzing the association of LDL-C with 169 T2D, we also tested for interactions with sex and age and provided stratified analyses 170 accordingly.
For the genome-wide association study of LDL-C in the UK Biobank, the LDL-C level of individuals on cholesterol-lowering medication was corrected by dividing it by a correction 173 factor of 0.63 (30). We transformed LDL-C by inverse normalization. We used BOLT-LMM 174 software (31) to perform GWAS on individuals of European descent (n=431,167) and included 175 'last eating' time (see above), sex, age, age 2 , center, genotyping chip and the first 10 PCs as 176 covariates. BOLT-LMM performs a linear mixed model regression that includes a random effect 177 of all SNP genotypes other than the one being tested. We aligned effect sizes across the GWAS 178 summary statistics of each trait to the same effect allele using the harmonize function, as 179 mentioned above. We then selected only those SNPs that exhibited opposite directions of effects 180 for LDL-C and T2D. Among these, we selected only those with an association p-value < 5 × 10 -5 181 for LDL-C and for T2D in a region defined as a maximum size of 500 kb. At this p-value 182 threshold, the prior probability of a given SNP associated with two traits and with discordant 183 direction of effect under the null hypothesis, corresponds to 0.00005 × 0.000025 = 1.25 × 10 -9 184 (32). We did not employ a multivariate approach because current methods do not typically report 185 trait-specific effect size estimates (or directions). Although MTAG (33) does provide effect size 186 estimates for each trait, this method is not suitable for traits with low genetic correlation, which 187 is the case for LDL-C and T2D (25). For the replication of the discovered loci, we used a 188 threshold of p<5 × 10 -3 in GLGC (does not include UK Biobank individuals), and exhibiting the 189 opposite direction of association with T2D in DIAGRAM. To test the association of the 31 SNPs 190 (T2D increasing allele) that we identified with a range of other cardiometabolic traits, we used 191 similar methods described above for the LDL-C GWAS. For TG and HDL-C, we excluded 192 individuals reporting cholesterol-lowering medication. For ALT and AST, we excluded 15,138 193 individuals with medical conditions, other than NAFLD, that could affect liver enzyme levels (34). For HbA1c, we excluded individuals with self-reported T2D (see above). For WHR, we 195 additionally adjusted for BMI prior to inverse normalization and subsequent GWAS. We inverse 196 normalized all traits before GWAS. After association of 31 SNPs with each of these seven 197 additional phenotypes, we normalized the effect sizes by dividing the beta coefficients by the 198 corresponding standard errors, and dividing by the square root of the respective sample size. We 199 then used hierarchical clustering to group the identified variants according to their pattern of 200 association with all nine traits, including T2D and LDL-C. We used the hclust function in R, 201 with the Euclidian metric to calculate distances, and the Ward clustering method (35).
203
Results
204
Participant characteristics 205
In a sample size of 379,617 individuals after exclusions of individuals on lipid-lowering 206 medication, T2D prevalence was 0.9%, and was higher in males (1.53 %) than females (0.63 %).
207
Individuals with T2D had lower LDL-C, higher TG, higher HbA1c, and higher BMI (see 208 Supplementary Table 1 ).
210
Association of LDL-C with T2D 211
We observed an inverse relationship between LDL-C and T2D prevalence (T2D 212 prevalence = 0.90%; OR=0.43 [0.41, 0.45], p=2.6 × 10 -269 ). Individuals in the lowest decile of 213 LDL-C exhibited the highest prevalence of T2D and a consistent decrease in T2D prevalence 214 was observed with increasing LDL-C (see Figure 1 ). We found a very similar negative association of LDL-C with T2D among only the individuals reporting the use of cholesterol-216 lowering medication. We found a significant interaction of LDL-C with sex (p=1.2 × 10 -18 ), 217 whereby the association of LDL-C with T2D was stronger among men (OR=0. 36 Table 2 and Supplementary Figure 1) . We also observed a stronger inverse association between 220 LDL-C and T2D prevalence among older individuals (Supplementary Table 2 Figure 3 ).
227
Loci associated inversely with LDL-C and T2D 228 We identified 48 loci associated in opposite directions with LDL-C and T2D using the 229 C and higher T2D risk, we identified 24 novel loci exerting opposite-direction effects on these 261 traits. Our analyses lend weight to the notion that the association between lower LDL-C and 262 increased T2D risk is driven, at least in part, by a specific group of genetic variants that may be 263 implicated via diverse mechanisms including hepatic lipid synthesis, export, and uptake, as well 264 as insulin secretion and action. These variants provide insight into the heterogeneous outcomes 265 for different lipid and glucose metabolism pathways and may also point to novel susceptibility 266 loci for hyperlipidemia and T2D.
267
We find that low LDL-C is associated with greater T2D risk, which is consistent with two 268 previous studies examining T2D prevalence (8) and incidence (9). In addition, we find that lower 269 LDL-C is associated with lower HbA1c (among individuals without T2D) and lower BMI. On 270 the other hand, we do observe a similar inverse relationship of LDL-C with T2D in the set of 271 people on cholesterol-lowering medication. We also find that unlike LDL-C, TG levels are 272 positively associated with T2D prevalence. This opposing relationship of LDL-C and TG with 273 T2D suggests that LDL are being overfilled in individuals with T2D.
274
Previous research into loci that jointly alter the risk for LDL-C and T2D has focused on 275 the genomic targets of lipid-lowering medications, in the hope that these analyses will give 276 specific insights into associated T2D risk. Our analyses confirmed that variants in HMGCR (36) 277 and NPC1L1 (19) are associated with lower LDL-C and increased T2D risk. On the other hand, 278 our analyses did not identify variants at PCSK9. The lowest T2D p-value was 0.003 in this 279 region for a SNP with opposite direction coefficient. However, our analyses identified a fourth 
